NHMRC is investing $55 million towards 11 outstanding teams of researchers, from a range of disciplines, who will answer major health and medical research questions that cannot be answered by a single researcher through NHMRC Synergy Grants.
A multidisciplinary team led by the Children's Medical Research Institute's researcher, Professor Hilda Pickett, is aiming to understand of how Alternative Lengthening of Telomeres works at the molecular level in cancer cells, with the ultimate goal of developing the first targeted treatments for aggressive and hard to treat cancers.
Professor Carol Hodgson of the University of Melbourne will lead a project aiming to improve personalised care in critically ill patients, which will inform safe clinical practice, national guidelines and policies.
University of Queensland researcher, Professor Abdullah Mamun, will work with Aboriginal and Torres Strait Islander people to develop and implement evidence based knowledge and culturally appropriate practices to end rheumatic heart disease in Australia, while building capabilities among researchers, communities, and community controlled health organisations.
Professor Kirsten McCaffery from the University of Sydney will lead a project aiming to ensure that AI-driven healthcare is underpinned by health literacy evidence and principles and informed by community from the outset so that it is inclusive to all.
This announcement supports the Australian Government's commitment to identifying new treatments, tests and preventions for health issues through funding investments into health and medical research.
Full details of the researchers and all projects funded are available to download on NHMRC's outcomes of funding rounds page.
Quotes attributable to NHMRC CEO, Professor Steve Wesselingh:
"Synergy Grants empower exceptional multidisciplinary teams to tackle significant questions in human health, and it is a true testament to the power of working together.
"This scheme fosters collaboration among diverse researchers, spanning gender, career stages, and cultural backgrounds, to solve major health challenges from discovery to translation and I can't wait to see the outcomes."
